SLU-PP-915 quick reference
What is SLU-PP-915?
Close relative of SLU-PP-332 that works by mouth in mice.
Sold as an oral exercise mimic.
Mice and cells only. No human trials.
How SLU-PP-915 works
Activates ERR alpha, beta and gamma.
Raised Ddit4 in muscle as much as treadmill running.
Active by mouth in mice, unlike 332.
With training, gene response rose further.
What SLU-PP-915 is studied for
Mice ran farther and longer, injected or by mouth.
Ddit4 matched or beat treadmill-running levels.
Heart-failure mice improved heart function.
Found in a new ERR agonist series.
Metabolites mapped for anti-doping tests.
SLU-PP-915 dosing protocol
| Item | What is known |
|---|---|
| Human dose | Not established |
| Studied in | Mice (injection into the belly cavity, IP) |
| Mouse dose | 25 mg/kg, twice a day, 6 weeks (heart failure model) |
| Mouse oral | Active by mouth in mice (JPET 2026); dose not read |
From the Circulation 2024 paper (PubMed 37961903). The only drug-level data for 915 was one 20 mg/kg injection. Do not convert mouse doses into human doses.
Label and trial amounts come from the sources below. Community amounts are what people report; they have not been tested.
Mixing
Oral capsule. No mixing needed.
What the research found
No human results exist. In a mouse model of heart failure:
Circulation 2024 (PubMed 37961903): treated mice had better heart pumping, less scarring and survived longer. Mouse results only.
SLU-PP-915 community experience
What users report. Not tested in trials.
Positive reports
- Oral option Seen as the fix for 332's weak oral exposure.
- Different target Acts on exercise genes, not appetite.
- Direct comparison Mouse papers tested it against 332.
Negative & mixed
- No human data Nothing shows a benefit in people.
- Unknown capsules Retail product may differ from study material.
- Forum doses Posted doses are not backed by trials.
SLU-PP-915 stacking
In mice, training plus 915 raised gene response more.
ERR plus AMPK pathways. Not studied together.
Different pathways. Not studied together.
SLU-PP-915 side effects & safety
Common
- No human safety data exists.
- No human dose or exposure range is known.
- Mouse studies were short.
- Product quality varies outside studies.
Less common
- Effects of long ERR activation are unknown.
- Heart results come from a mouse disease model.
- No data in pregnancy or chronic illness.
Precautions
- Pregnancy or breastfeeding: no data.
- Prescription drugs: interactions unstudied.
- Do not turn mouse doses into human doses.
- Check that testing confirms the named compound.
Our verdict on SLU-PP-915
Better oral data than 332, but still mouse only. No human dose exists.
SLU-PP-915 FAQ
Is SLU-PP-915 better than 332?
In mice it works by mouth; 332 does not.
Is it a peptide?
No. It is a small molecule.
Is there a human dose?
No. No human trial exists.
Sources
- Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation 2024 (PubMed 37961903)
- Review: Pharmacological activation of ERR as an exercise mimetic. Rev Med Chil 2026 (PubMed 42024694)
- ClinicalTrials.gov search for SLU-PP-915, 5 Nov 2026: no registered studies
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther 2026 (PubMed 41421047)
- Development of a new chemical series of pan-ERR agonists, identification of SLU-PP-915. Eur J Med Chem 2023 (PubMed 37421886)
- In vitro metabolism of SLU-PP-332 and SLU-PP-915. Rapid Commun Mass Spectrom 2026 (PubMed 41588687)